Skip to main content

Table 2 Study timeline

From: Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial

Visit Screening Baseline visita Treatment        
Visit number 1 2 3 4 5 6 7 8 9 10
Weeks (w) −2 w to −1 d 0 1 w 2 w 4 w 8 w 12 w 16 w 20 w 24 w
Visit window NA NA ±4 d ±4 d ±1 w ±2 w ±2 w ±2 w ±2 w ±2 w
Consent X          
Randomization   X         
Medical history X          
Physical examination X   X X X X X X X X
Neurologic examination X   X X X X X X X X
Xpert MTB/RIF® assay X          
Sputum AFB smear X Xd X X X X X X X X
TB culture (solid) X Xd X X X X X X X X
TB culture (liquid) X Xd X X X X X X X X
DSTb With first cultured Mycobacterium tuberculosis
CXR X Xd    X X X X X X
HIV, HBV X          
Total bilirubin, AST/ALT, creatinine X Xd X X X X X X X X
Complete blood count X Xd X X X X X X X X
Optic test   X X X X X     
Urine HCGc X          
Compliance of drug intake    X X X X X X X X
Adverse drug reaction    X X X X X X X X
Other medicationse   X X X X X X X X X
  1. w weeks, d days, NA not applicable, AFB acid-fast bacilli, TB tuberculosis, DST drug susceptibility test, CXR simple chest radiography, HIV human immunodeficiency virus, HBV hepatitis B virus, AST aspartate transaminase, ALT alanine transaminase, HCG human chorionic gonadotropin
  2. aTreatment will be initiated at the baseline visit, as TB treatment should be started promptly following diagnosis
  3. bDrug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin, prothionamide, cycloserine, and para-aminosalicylic acid
  4. cOnly in females of childbearing potential
  5. dCan be omitted if the results of previous tests within the prior 4 weeks are available
  6. eIn particular, immunosuppressive agents (including corticosteroids)